| TTM
|
12/31/2025
|
12/31/2024
|
12/31/2023
|
12/31/2022
|
|
|---|---|---|---|---|---|
| Total Revenue
|
0 | 0 | 0 | 0 | 0 |
| Cost of Revenue
|
0 | 0 | 0 | 0 | 0 |
|
Gross Profit
|
0 | 0 | 0 | 0 | 0 |
| Selling, General and Administrative Expenses
|
-1,129 | -1,129 | -759 | -734 | -850 |
|
Research and Development Expenses
|
-28 | -28 | -16 | -31 | -30 |
| Depreciation, Amortization and Depletion
|
-31 | -- | -31 | -- | 0 |
|
Other Income/Expense, Operating
|
-223 | -223 | 0 | 0 | -- |
|
Operating Income/Expenses
|
-1,380 | -1,380 | -775 | -765 | -880 |
|
Total Operating Profit/Loss
|
-1,380 | -1,380 | -775 | -765 | -880 |
| Total Net Finance Income/Expense
|
-26 | -26 | -52 | 37 | 25 |
| Net Investment Income
|
955 | 955 | 1,067 | -1,054 | -493 |
| Irregular Income/Expenses
|
-308 | -308 | 0 | 0 | -- |
|
Non-Operating Income/Expenses, Total
|
621 | 621 | 1,015 | -1,017 | -468 |
|
Pretax Income
|
-759 | -759 | 240 | -1,782 | -1,348 |
|
Provision for Income Tax
|
0 | 0 | 0 | 0 | 0 |
|
Net Income from Continuing Operations
|
-759 | -759 | 240 | -1,782 | -1,348 |
|
Discontinued Operations
|
-6,210 | -6,210 | -1,267 | 0 | -- |
|
Net Income after Extraordinary Items and Discontinued Operations
|
-6,969 | -6,969 | -1,027 | -1,782 | -1,348 |
|
Net Income after Non-Controlling/Minority Interests
|
-6,969 | -6,969 | -1,027 | -1,782 | -1,348 |
|
Net Income Available to Common Stockholders
|
-6,969 | -6,969 | -1,027 | -1,782 | -1,348 |
|
Dilution to Earnings
|
-- | -- | -- | 0 | -- |
|
Diluted Net Income Available to Common Stockholders
|
-6,969 | -6,969 | -1,027 | -1,782 | -1,348 |
| Basic EPS
|
-3.20 | -3.20 | -0.80 | -1.20 | -0.80 |
| Diluted EPS
|
-3.20 | -3.20 | -0.80 | -1.20 | -0.80 |
|
Basic Weighted Average Shares Outstanding
|
2,240.4360 | 2,240.4360 | 1,682.6120 | 1,362.2650 | 1,362.2650 |
|
Diluted Weighted Average Shares Outstanding
|
2,240.4360 | 2,240.4360 | 1,682.6120 | 1,362.2650 | 1,362.2730 |
| Income Statement, Supplemental
|
|||||
|
EBIT
|
-812 | -812 | 234 | -1,823 | -1,384 |
|
EBITDA
|
-812 | -812 | 433 | -1,823 | -1,383 |
|
Normalized EBITDA
|
5,168 | 5,168 | -396 | -798 | -892 |
12/31/2022 - 9/1/2005
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
Upgrade